Insights From JUPITER-02: Plasma EBV Levels and Toripalimab in R/M NPC
A panelist discusses how low baseline EBV levels still showed benefit from toripalimab in JUPITER-02, though EBV status influences treatment decisions and alternative markers are needed for EBV-negative cases.
Video content above is prompted by the following:
- Please review subgroup analyses from JUPITER-02 for EBV copy number at baseline.
- The patient had detectable but low plasma EBV levels (under 2000 IU/ml).
- What are your thoughts on overall survival between treatment arms for patients with a baseline plasma EBV copy number of less than 2000 IU/ml?
- Please continue to discuss the role of EBV titers and treatment decisions.
- How do plasma EBV levels influence your treatment approach?
- Do your expectations regarding response to therapy change based on plasma EBV levels?
- What if a patient has EBV-negative disease?
- Are there other disease response indicators that might be useful in this patient population?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
